BioLife Solutions, Inc.

NasdaqCM:BLFS Voorraadrapport

Marktkapitalisatie: US$1.2b

BioLife Solutions Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van BioLife Solutions is gedaald met een gemiddeld jaarlijks percentage van -45%, terwijl de winst van de Life Sciences -industrie jaarlijks groeide met 11.7%. De inkomsten zijn groeide met een gemiddeld percentage van 28.6% per jaar.

Belangrijke informatie

-45.0%

Groei van de winst

-40.2%

Groei van de winst per aandeel

Life Sciences Groei van de industrie21.5%
Inkomstengroei28.6%
Rendement op eigen vermogen-15.2%
Nettomarge-33.6%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Nov 15
Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Aug 30
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

Aug 14
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05
A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14
Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13
Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11
Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17
Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Aug 11
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

May 06
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Feb 22
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Jan 10
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

BioLife: What The Future Holds

Oct 19

Opbrengsten en kosten

Hoe BioLife Solutions geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:BLFS Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 24147-497415
30 Jun 24140-647517
31 Mar 24141-627818
31 Dec 23143-668019
30 Sep 23126-796915
30 Jun 23143-747015
31 Mar 23155-1417014
31 Dec 22162-1406915
30 Sep 22155-1066714
30 Jun 22148-966414
31 Mar 22139-155714
31 Dec 21119-94812
30 Sep 219753810
30 Jun 21744299
31 Mar 2153-20237
31 Dec 20482227
30 Sep 20427186
30 Jun 203716175
31 Mar 203439154
31 Dec 1927-2143
30 Sep 1925-32122
30 Jun 1923-39112
31 Mar 1922-44101
31 Dec 1820-2591
30 Sep 1817181
30 Jun 1815071
31 Mar 1812-271
31 Dec 1711-371
30 Sep 1710-561
30 Jun 179-672
31 Mar 179-772
31 Dec 168-782
30 Sep 168-582
30 Jun 167-582
31 Mar 167-482
31 Dec 156-471
30 Sep 156-471
30 Jun 156-461
31 Mar 156-461
31 Dec 146-351
30 Sep 147-351
30 Jun 148-241
31 Mar 149-241
31 Dec 139-140

Kwaliteitswinsten: BLFS is momenteel verliesgevend.

Groeiende winstmarge: BLFS is momenteel verliesgevend.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: BLFS is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 45% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van BLFS over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: BLFS is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Life Sciences industrie ( -4.7% ).


Rendement op eigen vermogen

Hoge ROE: BLFS heeft een negatief Return on Equity ( -15.19% ), omdat het momenteel verliesgevend is.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden